Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health technology assessment (HTA). The Reassessment and Uptake...

Full description

Bibliographic Details
Main Authors: Wei Fang Dai, Vanessa Arciero, Erica Craig, Brent Fraser, Jessica Arias, Darryl Boehm, Nevzeta Bosnic, Patricia Caetano, Carole Chambers, Barry Jones, Elena Lungu, Gunita Mitera, Tanya Potashnik, Anthony Reiman, Trevor Ritcher, Jaclyn M. Beca, Avram Denburg, Rebecca E. Mercer, Ambica Parmar, Mina Tadrous, Pam Takhar, Kelvin K. W. Chan, on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Current Oncology
Subjects:
health technology assessment
real-world evidence
reassessment
Online Access:https://www.mdpi.com/1718-7729/28/5/354

Similar Items

Similar Items